Intravenous Immunoglobulin Market Outlook 2031
- The global intravenous immunoglobulin market was valued at US$ 11.2 Bn in 2021
- It is estimated to grow at a CAGR of 7.3% from 2022 to 2031
- The global intravenous immunoglobulin market is expected to reach value of US$ 20.5 Bn by the end of 2031
Request a PDF Sample – https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1930
Analysts’ Viewpoint on Intravenous Immunoglobulin Market Scenario
The global intravenous immunoglobulin market is driven by the rise in the global prevalence of autoimmune diseases such as multiple sclerosis, immune thrombocytopenia purpura (ITP), autoimmune hemolytic anemia, and Kawasaki syndrome. The global intravenous immunoglobulin market is projected to witness significant growth over the next few years due to technological advancements leading to the development of new production and purification methods. Rapid increase in the number of neurological disorders, rise in the global geriatric population, and expansion of patient pool have fueled the demand for quick and reliable treatment measures. Furthermore, all companies should increase their R&D efforts in the development of novel products to broaden their revenue streams.
Request for Analysis of COVID19 Impact on Intravenous Immunoglobulin (IVIG) Market – https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=1930
Overview of Intravenous Immunoglobulin Market
Immunoglobulins are highly purified, sterile-specific medical therapy solutions containing gamma globulin G (IgG) in a concentration of 95% or more. These are manufactured from a highly refined pool of human plasma collected from at least 100 donors or more. Immunoglobulins can be administered through three different routes such as intramuscular, intravenous, and subcutaneous. The intramuscular route of administration is a relatively older method and is not preferred presently, as it is painful. Intravenous immunoglobulin has emerged as a boon in the last few decades for patients with compromised immune systems.
Request a PDF Brochure – https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1930
Rise in R&D Activities in Intravenous Immunoglobulin To Fuel Market Growth
Increasing adoption of immunoglobulin, along with a surge in frequency of product launches and prompt approval from government regulatory bodies across the world is expected to fuel the demand during the forecast period. According to an October 2020 update by the National Institutes of Health, a clinical trial to test the safety, tolerability, and efficacy of a combination treatment regimen for coronavirus disease 2019 (COVID-19) consisting of the antiviral Remdesivir plus, a highly concentrated solution of antibodies that neutralize SARS-CoV-2, the virus that causes COVID-19, was initiated in 2020. The study was performed on hospitalized adults with COVID-19 in the U.S., Mexico, and 16 other countries on five continents.
The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, sponsored and funded the phase 3 trial, called Inpatient Treatment with Anti-Coronavirus Immunoglobulin, or ITAC. The antibody solution that was tested in the ITAC trial is anti-coronavirus hyperimmune intravenous immunoglobulin or hIVIG. Moreover, the rise in the number of government initiatives supporting the usage of the intravenous mode of delivery for some medications propels the global market. For instance, in June 2021, the Ministry of Health and Family Welfare of Karnataka, India, decided to procure an intravenous immunoglobulin (IVIG) drug worth more than INR 10 Cr for emergency use among children.
Enquiry before Buying Intravenous Immunoglobulin (IVIG) Market Report – https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=1930
Surge in incidence of Primary Immunodeficiency Diseases to Drive Global Market
In terms of indication, the global intravenous immunoglobulin market has been classified into chronic inflammatory demyelinating polyneuropathy (CIDP), primary humoral immunodeficiency, idiopathic thrombocytopenic purpura (ITP), Guillain-Barre syndrome, myasthenia gravis, multifocal motor neuropathy (MMN), Kawasaki disease, hypogammaglobulinemia, chronic lymphocytic leukemia, and others. The hypogammaglobinemia segment dominated the global market in 2021. This can be attributed to increase in incidence of primary immunodeficiency diseases (PID) across the globe. It is the most common chronic immune defect in patients with lymphoproliferative disorders (LPDs).
More Trending Reports by Transparency Market Research:
About Us
Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.
Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.
TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.
Contact Us
Rohit Bhisey
Transparency Market Research,
90 State Street, Suite 700,
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
